You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Infectious Disease Specialist Perspectives on CMV Management in Transplant Patients: New Data and New Options 

  • Authors: Daniel R. Kaul, MD; Roy F. Chemaly, MD, MPH, FIDSA, FACP; Hannah Imlay, MD, MS
  • CME / ABIM MOC / CE Released: 11/16/2022
  • Valid for credit through: 11/16/2023, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    Nurses - 1.00 ANCC Contact Hour(s) (0.75 contact hours are in the area of pharmacology)

    Pharmacists - 1.00 Knowledge-based ACPE (0.100 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for infectious disease specialists, internal medicine and primary care physicians, transplant specialists (solid organ and hematopoietic stem cell transplants), transplant pharmacists, advanced practice providers (nurse practitioners/physician assistants), and other healthcare professionals interested in the management of CMV infection following transplantation.

The goal of this activity is that learners will be better able to understand of the role of new treatments for CMV infection in post-transplant patients and how best to incorporate them into patient care.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Identification of transplant patients at high risk of CMV 
    • Key differences in available treatments for CMV
  • Have greater competence related to
    • Management of resistant/refractory CMV 
  • Demonstrate greater confidence in their ability to
    • Optimize individualized management strategies for CMV in post-transplant patients in a multidisciplinary team environment


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Daniel R. Kaul, MD

    Professor of Internal Medicine
    Director, Transplant Infectious Disease
    Program Director, ID Fellowship Program
    University of Michigan
    Ann Arbor, Michigan


    Daniel R. Kaul, MD, has the following relevant financial relationships: 
    Research funding from: AstraZeneca; Gilead; Janssen; Merck; Nobelpharma; Takeda 
    Other: Data and Safety Monitoring Board Chair: Noveome


  • Roy F. Chemaly, MD, MPH, FIDSA, FACP

    Professor of Medicine
    Chief Infection Control Officer
    Director, Clinical Virology Research
    Department of Infectious Diseases, Infection Control, and Employee Health
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas


    Roy F. Chemaly, MD, MPH, FIDSA, FACP, has the following relevant financial relationships: 
    Consultant or advisor for: ADMA Biologics; AiCuris; Ansun Biopharma; Genentech; Janssen; Karius; Merck; Molecular Partners; Oxford Immunotec; Pulmotec; Takeda; Viracor-Eurofins 
    Speaker or member of speakers bureau for: Merck
    Research funding from: AiCuris; Ansun Biopharma; Genentech; Karius; Merck; Takeda; Viracor-Eurofins
    Stock options from: Xenex

  • Hannah Imlay, MD, MS

    Assistant Professor of Medicine
    University of Utah
    Salt Lake City, Utah


    Hannah Imlay, MD, MS, has no relevant financial relationships.


  • Anne M. Sendaydiego, PharmD

    Medical Education Director, WebMD Global, LLC


    Anne M. Sendaydiego, PharmD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-22-246-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Infectious Disease Specialist Perspectives on CMV Management in Transplant Patients: New Data and New Options 

Authors: Daniel R. Kaul, MD; Roy F. Chemaly, MD, MPH, FIDSA, FACP; Hannah Imlay, MD, MSFaculty and Disclosures

CME / ABIM MOC / CE Released: 11/16/2022

Valid for credit through: 11/16/2023, 11:59 PM EST


Learning Feedback Questions

Before you begin, please take this brief survey.

  • Print